Amarin Corporation has completed the treatment phase of both the North American and European phase III clinical trials with Miraxion for the treatment of Huntington's disease.

Amarin Corporation has successfully enrolled its target of 300 patients at 42 neurology centers in the US and Canada for its phase III clinical trial of Miraxion in Huntington's disease.